SCHEMBL26977050

SCHEMBL26977050

Cc1cn(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2F)c2ccc([N+](=O)[O-])cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ BRD4 O60885 1/20 0.47
▸ MAPT P10636 5/20 0.46
▸ MAPK1 P28482 5/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ JAK2 O60674 3/20 0.46
▸ CDK2 P24941 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ AURKA O14965 2/20 0.43
▸ JAK3 P52333 2/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ TYK2 P29597 1/20 0.43
▸ CCNB2 O95067 1/20 0.43
▸ CDK1 P06493 1/20 0.43
▸ CDK4 P11802 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26977136 0.90 CCND3 (0.49) SMN1; SMN2BRD4MAPTMAPK1KMT2A
SCHEMBL29113553 0.87 MAPT (0.45) SMN1; SMN2NPC1RAB9AMAPTKMT2A
SCHEMBL26980492 0.86 SYK (0.56) SYKSMN1; SMN2NPC1RAB9ABRD4
SCHEMBL30671838 0.84 JAK2 (0.48) SMN1; SMN2BRD4MAPTMAPK1KMT2A
SCHEMBL26977065 0.84 JAK2 (0.48) SMN1; SMN2BRD4MAPTMAPK1KMT2A
SCHEMBL29113559 0.82 JAK2 (0.49) SYKSMN1; SMN2NPC1RAB9AJAK2
SCHEMBL30671851 0.82 JAK2 (0.49) SYKSMN1; SMN2NPC1RAB9AJAK2
SCHEMBL26979838 0.82 BTK (0.56) SYKJAK2JAK3JAK1TYK2
SCHEMBL29113552 0.81 — —
SCHEMBL29929298 0.81 CDK2 (0.41) SYKBRD4MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190849-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE TYRA BIOSCIENCES, INC. 2024-06-13 — — US disclosed
EP-4297873-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE Tyra Biosciences, Inc. (US) 2024-01-03 — — EP disclosed
CN-117136184-A Aminopyrimidine compounds and methods of use thereof 泰拉生物科学公司 2023-11-28 — — CN disclosed
WO-2022182972-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE TYRA BIOSCIENCES, INC. (US) 2022-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190849-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE DPYD, TYMP, TYMS SYK 2704/4885SMN1; SMN2 1317/4885NPC1 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback